LAUSR

Author's summary Pulmonary tumor thrombotic microangiopathies (PTTMs) are rare but devastating events in cancer patients. Because there are not many of these diseases, little is known about the disease course, and no clear treatment methods are suggested. Therefore, we have no choice but to rely on the empirical treatment of clinicians. In this study, the average disease course of PTTM and the underlying characteristics of PTTM predisposition were identified. Although chemotherapy has been demonstrated to be effective in this study, death within hours or months is inevitable, so it is necessary to prepare for the end-of-life care when PTTM is diagnosed.